Common use of Commercialization of Licensed Products Clause in Contracts

Commercialization of Licensed Products. With respect to each Licensed Product developed and commercialized by Schering, or its designated Affiliates, under this Agreement, Schering shall be solely responsible, at its sole expense, for all aspects of the development and commercialization of the Licensed Product in the Territory, including, without limitation: *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. (i) the manufacture of Designated Compounds and Licensed Products in accordance with the applicable Regulatory Approvals, laws, Good Laboratory Practices and Good Manufacturing Practices; (ii) preparation, filing, obtaining, maintaining and supporting, in its own name or that of its designated Affiliate, with the appropriate regulatory authorities of all regulatory approvals, authorizations, permits and licenses (including, without limitation, all Regulatory Approvals) that are necessary to conduct clinical studies of Licensed Products and/or to manufacture, import, distribute, market and sell Licensed Products; (iii) the reporting all adverse events associated with any Licensed Product to the appropriate regulatory authorities in accordance with applicable laws, rules and regulations in the Territory; and (iv) the distribution, marketing, promotion and sale of Licensed Products. Following the expiration of the Screening Program, Schering shall provide NeoGenesis with semi-annual reports summarizing the status of Schering's development and commercialization activities with respect to each Licensed Product being developed under this Agreement. In addition, Schering shall notify NeoGenesis in writing upon the filing of each application for Regulatory Approval of a Licensed Product in the Territory.

Commercialization of Licensed Products. With respect to each Licensed Product developed and commercialized by ScheringSPL, or its designated Affiliates, under this Agreement, Schering SPL shall be solely responsible, at its sole expense, for all aspects of the development and commercialization of the Licensed Product in the Territory, including, without limitation: *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.: (i) the manufacture of Designated Compounds and Licensed Products in accordance with the applicable Regulatory Approvals, laws, Good Laboratory Practices and Good Manufacturing Practices; (ii) preparation, filing, obtaining, maintaining and supporting, in its own name or that of its designated Affiliate, with the appropriate regulatory authorities of all regulatory approvals, authorizations, permits and licenses (including, without limitation, all Regulatory Approvals) that are necessary to conduct clinical studies of Licensed Products and/or to manufacture, import, distribute, market and sell Licensed Products; (iii) the reporting all adverse events associated with any Licensed Product to the appropriate regulatory authorities in accordance with applicable laws, rules and regulations in the Territory; andand * = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. (iv) the distribution, marketing, promotion and sale of Licensed Products. Following the expiration of the Screening Program, Schering SPL shall provide NeoGenesis with semi-annual reports summarizing the status of ScheringSPL's development and commercialization activities with respect to each Licensed Product being developed under this Agreement. In addition, Schering SPL shall notify NeoGenesis in writing upon the filing of each application for Regulatory Approval of a Licensed Product in the Territory.

Commercialization of Licensed Products. With respect to each Licensed Product developed and commercialized by ScheringSPL, or its designated Affiliates, under this Agreement, Schering SPL shall be solely responsible, at its sole expense, for all aspects of the development and commercialization of the Licensed Product in the Territory, including, without limitation: *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.: (i) the manufacture of Designated Compounds and Licensed Products in accordance with the applicable Regulatory Approvals, laws, Good Laboratory Practices and Good Manufacturing Practices; (ii) preparation, filing, obtaining, maintaining and supporting, in its own name or that of its designated Affiliate, with the appropriate regulatory authorities of all regulatory approvals, authorizations, permits and licenses (including, without limitation, all Regulatory Approvals) that are necessary to conduct clinical studies of Licensed Products and/or to manufacture, import, distribute, market and sell Licensed Products;; *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. (iii) the reporting all adverse events associated with any Licensed Product to the appropriate regulatory authorities in accordance with applicable laws, rules and regulations in the Territory; and (iv) the distribution, marketing, promotion and sale of Licensed Products. Following the expiration of the Screening Program, Schering SPL shall provide NeoGenesis with semi-annual reports summarizing the status of ScheringSPL's development and commercialization activities with respect to each Licensed Product being developed under this Agreement. In addition, Schering SPL shall notify NeoGenesis in writing upon the filing of each application for Regulatory Approval of a Licensed Product in the Territory.

Commercialization of Licensed Products. With respect to each Licensed Product developed and commercialized by Schering, or its designated Affiliates, under this Agreement, Schering shall be solely responsible, at its sole expense, for all aspects of the development and commercialization of the Licensed Product in the Territory, including, without limitation: *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.: (i) the manufacture of Designated Compounds and Licensed Products in accordance with the applicable Regulatory Approvals, laws, Good Laboratory Practices and Good Manufacturing Practices; (ii) preparation, filing, obtaining, maintaining and supporting, in its own name or that of its designated Affiliate, with the appropriate regulatory authorities of all regulatory approvals, authorizations, permits and licenses (including, without * = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. limitation, all Regulatory Approvals) that are necessary to conduct clinical studies of Licensed Products and/or to manufacture, import, distribute, market and sell Licensed Products; (iii) the reporting all adverse events associated with any Licensed Product to the appropriate regulatory authorities in accordance with applicable laws, rules and regulations in the Territory; and (iv) the distribution, marketing, promotion and sale of Licensed Products. Following the expiration of the Screening Program, Schering shall provide NeoGenesis with semi-annual reports summarizing the status of Schering's development and commercialization activities with respect to each Licensed Product being developed under this Agreement. In addition, Schering shall notify NeoGenesis in writing upon the filing of each application for Regulatory Approval of a Licensed Product in the Territory.